Radiopharm Theranostics Limited - ADR earnings per share and revenue
On Sep 25, 2025, RADX reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.01 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Lexaria Bioscience Corp. Common Stock
Report Date
Jan 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+47.21%
Anixa Biosciences, Inc.
Report Date
Jan 12, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.09
Surprise
-0.78%
FAQ
What were Radiopharm Theranostics Limited - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Radiopharm Theranostics Limited - ADR reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Radiopharm Theranostics Limited - ADR's Q4 2025 earnings?
The stock price moved -- 0%, changed from $5.75 before the earnings release to $5.75 the day after.
When is Radiopharm Theranostics Limited - ADR expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Radiopharm Theranostics Limited - ADR's next earnings report?
Based on --
analysts, Radiopharm Theranostics Limited - ADR is expected to report EPS of -- and revenue of -- for Q-- --.